DA5 Disease State Management Tracker: Implementing, Tracking, and Evaluating Clinical Pathways and OutcomesAJ AmbegaonkarValue in Health1998DOI 10.1046/j.1524-4733.1998.1100875.x
A New Dental Anxiety Scale for 5-year-old Children (DA5): Description and Concurrent ValidityHumphris, G.M.Health Education Journal2002DOI 10.1177/001789690206100102
Evaluating the Potential of Marine Bacteriovorax Sp. DA5 as a Biocontrol Agent Against Vibriosis in Litopenaeus Vannamei LarvaeWen, ChongqingElsevier Science2014DOI 10.1016/j.vetmic.2014.07.022
Brain Uptake Pharmacokinetics of Albiglutide, Dulaglutide, Tirzepatide, and DA5-CH in the Search for New Treatments of Alzheimer’s and Parkinson’s DiseasesElizabeth M. RheaInforma UK Limited2023DOI 10.1080/21688370.2023.2292461
The novel GLP‐1/GIP analogue DA5‐CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of ADLi, ChengWiley (John Wiley & Sons)2020DOI 10.1002/brb3.1505
DA5-CH, a Novel GLP-1/GIP Dual Agonist, Effectively Ameliorates the Cognitive Impairments and Pathology in the APP/PS1 Mouse Model of Alzheimer's DiseaseCao, YueElsevier Science2018DOI 10.1016/j.ejphar.2018.03.024
Molecular mechanical studies of base-pair opening in d(CGCGC):d(GCGCG), dG5·dC5, d(TATAT):d(ATATA), and dA5·dT5 in the B and Z forms of DNAJoe KeepersWiley (John Wiley & Sons)2007DOI 10.1002/bip.360231124
The GLP‐1/GIP dual‐receptor agonist DA5‐CH inhibits the NF‐κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP‐1 single‐receptor agonist NLY01Lv, MiaoJunWiley2021DOI 10.1002/brb3.2231